14 December 2015 : Clinical Research
Cognitive Results of CANTAB Tests and Their Change Due to the First Dose of Donepezil May Predict Treatment Efficacy in Alzheimer DiseaseJurgita KuzmickienėABCDEF, Gintaras KaubrysABCDEF
Med Sci Monit 2015; 21:3887-3899
BACKGROUND: Ability to predict the efficacy of treatment in Alzheimer disease (AD) may be very useful in clinical practice. Cognitive predictors should be investigated alongside with the demographic, genetic, and other predictors of treatment efficacy. The aim of this study was to establish whether the baseline measures of CANTAB tests and their changes due to the first donepezil dose are able to predict the efficacy of treatment after 4 months of therapy. We also compared the predictive value of cognitive, clinical, and demographic predictors of treatment efficacy in AD.
MATERIAL AND METHODS: Seventy-two AD patients (62 treatment-naïve and 10 donepezil-treated) and 30 controls were enrolled in this prospective, randomized, rater-blinded, follow-up study. Treatment-naïve AD patients were randomized to 2 groups to take the first donepezil dose after the first or second CANTAB testing, separated by 4 hours. Follow-up Test 3 was performed 4 months after the initial assessment.
RESULTS: The groups were similar in age, education, gender, Hachinski index, and depression. General Regression Models (GRM) have shown that cognitive changes after the first dose of donepezil in PAL (t-values for regression coefficients from 3.43 to 6.44), PRMd (t=4.33), SWM (t=5.85) test scores, and baseline results of PAL (t=2.57–2.86), PRM (t=3.08), and CRT (t=3.42) tests were significant predictors of long-term donepezil efficacy in AD (p<0.05).
CONCLUSIONS: The cognitive changes produced by the first donepezil dose in CANTAB PAL, PRM, and SWM test measures are able to predict the long-term efficacy of donepezil in AD. Baseline PAL, PRM, and CRT test results were significant predictors.
Keywords: Cognition - drug effects, Alzheimer Disease - drug therapy, Aged, 80 and over, Indans - therapeutic use, Neuropsychological Tests, Nootropic Agents - therapeutic use, Piperidines - therapeutic use, Prospective Studies
01 December 2022 : EditorialEditorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic
Med Sci Monit 2022; 28:e939088
29 November 2022 : Clinical ResearchRetrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...
Med Sci Monit In Press; DOI: 10.12659/MSM.938647
07 December 2022 : Clinical ResearchA Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vacc...
Med Sci Monit 2022; 28:e938665
01 December 2022 : EditorialEditorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Funga...
Med Sci Monit 2022; 28:e939088
07 Dec 2022 : Review articleA Review of the Ethical Use of Animals in Functional Experimental Research in China Based on the “Four R” P...
Med Sci Monit In Press; DOI: 10.12659/MSM.938807
07 Dec 2022 : Meta-AnalysisPrevalence of Burnout in Healthcare Specialties: A Systematic Review Using Copenhagen and Maslach Burnout I...
Med Sci Monit In Press; DOI: 10.12659/MSM.938798
05 Dec 2022 : Database AnalysisImpact of the De Ritis Ratio on the Prognosis of Patients with Stable Coronary Artery Disease Undergoing Pe...
Med Sci Monit In Press; DOI: 10.12659/MSM.937737
Most Viewed Current Articles
13 Nov 2021 : Clinical ResearchAcceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
01 Nov 2020 : Review articleLong-Term Respiratory and Neurological Sequelae of COVID-19
Med Sci Monit 2020; 26:e928996